<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034460</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.109807</org_study_id>
    <nct_id>NCT03034460</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CD5024 1% in Acne Vulgaris</brief_title>
  <official_title>Efficacy and Safety of CD5024 1% in Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using
      intra-individual comparison involving subjects with acne vulgaris on face to evaluate the
      efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study drugs application will be performed once daily, 5 days a week during 6 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory acne lesion count per half face</measure>
    <time_frame>Day 40</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>CD5024 1% cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD5024 cream placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of active drug;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD0271/CD1579 gel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Positive control;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD0271/CD1579 gel placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo of positive control;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD5024 1% cream</intervention_name>
    <description>500 µL on half-face, five days a week during 6 weeks</description>
    <arm_group_label>CD5024 1% cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD5024 cream placebo</intervention_name>
    <description>500 µL on half-face, five days a week during 6 weeks</description>
    <arm_group_label>CD5024 cream placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD0271/CD1579 gel</intervention_name>
    <description>500 µL on half-face, five days a week during 6 weeks</description>
    <arm_group_label>CD0271/CD1579 gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD0271/CD1579 gel placebo</intervention_name>
    <description>500 µL on half-face, five days a week during 6 weeks</description>
    <arm_group_label>CD0271/CD1579 gel placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is a male or a female aged from 18 to 35 years old at screening visit.

          2. The subject has a medical diagnosis of acne vulgaris :

             2.1 at least 20 (twenty) inflammatory lesions and a maximum of 100 (one hundred)
             non-inflammatory lesions (nose is excluded for the lesion count) at Baseline

             2.2 symmetry of the lesions: No more than twice as many acne lesions on one side as
             compared to the other side at Baseline

          3. If the subject is a female of childbearing potential, she must agree to use an
             effective contraceptive method for the duration of the study

        Exclusion Criteria:

          1. The subject has an underlying known disease surgical or medical condition, in the
             opinion of the investigator might interfere with interpretation of the study results
             or put the subject at risk (e.g., other dermatological diseases affecting the
             treatment area, such as a dermatitis, eczema, etc., or any uncontrolled chronic or
             serious diseases which would normally prevent participation in any clinical study,
             such as a cancer, leukemia or severe hepatic impairment), (Screening).

          2. The subject has acne conglobata, acne fulminans, secondary acne (chloracne,
             drug-induced acne, etc.), nodulo cystic acne, or acne requiring systemic treatment.

          3. The subject has a known or suspected allergies or sensitivities to any components of
             any of the study drugs (see Investigator's Brochure/Product label).

          4. The subject is a male with beard or facial hair, which would interfere with clinical
             evaluation or clinical procedure (Screening and Baseline).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Investigational Site (# 8060)</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

